251 related articles for article (PubMed ID: 31423907)
1. Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.
Lou E; Nelson AC; Kool M
Cancer Biol Ther; 2019; 20(11):1398-1402. PubMed ID: 31423907
[TBL] [Abstract][Full Text] [Related]
2. Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib.
Lou E; Schomaker M; Wilson JD; Ahrens M; Dolan M; Nelson AC
Cancer Biol Ther; 2016 Oct; 17(10):1010-1016. PubMed ID: 27682250
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
5. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
6. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
[TBL] [Abstract][Full Text] [Related]
7. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
8. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
[TBL] [Abstract][Full Text] [Related]
9. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
[TBL] [Abstract][Full Text] [Related]
10. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
[TBL] [Abstract][Full Text] [Related]
11. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
[TBL] [Abstract][Full Text] [Related]
12. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.
Northcott PA; Hielscher T; Dubuc A; Mack S; Shih D; Remke M; Al-Halabi H; Albrecht S; Jabado N; Eberhart CG; Grajkowska W; Weiss WA; Clifford SC; Bouffet E; Rutka JT; Korshunov A; Pfister S; Taylor MD
Acta Neuropathol; 2011 Aug; 122(2):231-40. PubMed ID: 21681522
[TBL] [Abstract][Full Text] [Related]
13. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
14. Molecular therapy targeting Sonic hedgehog and hepatocyte growth factor signaling in a mouse model of medulloblastoma.
Coon V; Laukert T; Pedone CA; Laterra J; Kim KJ; Fults DW
Mol Cancer Ther; 2010 Sep; 9(9):2627-36. PubMed ID: 20807782
[TBL] [Abstract][Full Text] [Related]
15. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
[TBL] [Abstract][Full Text] [Related]
16. A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
Rodriguez-Blanco J; Li B; Long J; Shen C; Yang F; Orton D; Collins S; Kasahara N; Ayad NG; McCrea HJ; Roussel MF; Weiss WA; Capobianco AJ; Robbins DJ
Clin Cancer Res; 2019 Feb; 25(4):1379-1388. PubMed ID: 30487124
[TBL] [Abstract][Full Text] [Related]
17. CD271
Liang L; Coudière-Morrison L; Tatari N; Stromecki M; Fresnoza A; Porter CJ; Del Bigio MR; Hawkins C; Chan JA; Ryken TC; Taylor MD; Ramaswamy V; Werbowetski-Ogilvie TE
Cancer Res; 2018 Aug; 78(16):4745-4759. PubMed ID: 29930101
[TBL] [Abstract][Full Text] [Related]
18. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
Climans SA; Macdonald DR; Sutherland DE; Mason WP
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
[TBL] [Abstract][Full Text] [Related]
19. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
[TBL] [Abstract][Full Text] [Related]
20. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases.
Markant SL; Esparza LA; Sun J; Barton KL; McCoig LM; Grant GA; Crawford JR; Levy ML; Northcott PA; Shih D; Remke M; Taylor MD; Wechsler-Reya RJ
Cancer Res; 2013 Oct; 73(20):6310-22. PubMed ID: 24067506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]